BJS Open最新文献

{"title":"Treatment and survival of non-metastatic rectal cancer in patients with inflammatory bowel disease: nationwide cohort study.","authors":"Erik Lundqvist, Karin Westberg, Caroline E Dietrich, Åsa H Everhov, Pär Myrelid, Bengt Glimelius, Anna Martling, Caroline Nordenvall","doi":"10.1093/bjsopen/zraf014","DOIUrl":"10.1093/bjsopen/zraf014","url":null,"abstract":"<p><strong>Background: </strong>Patients with inflammatory bowel disease have an increased risk of colorectal cancer. There is a scarcity of large studies with a focus on rectal cancer in patients with inflammatory bowel disease. This study aimed to compare survival in resected patients with rectal cancer with and without inflammatory bowel disease.</p><p><strong>Methods: </strong>This national population-based study used the Colorectal Cancer Data Base. All Swedish patients ≥18 years of age with a diagnosis of stage I-III rectal cancer between 1997 and 2021, surgically treated with curative intent, were included and followed up until 2022. The outcome of interest was recurrence-free survival. Flexible parametric survival models adjusted for time since surgery, year of diagnosis, sex, age at diagnosis, and Charlson Co-morbidity Index were used to estimate proportional and time-dependent hazard ratios of recurrence-free survival with 95% confidence intervals.</p><p><strong>Results: </strong>Overall, 22 082 patients with rectal cancer were included, among whom 323 (1.5%) had inflammatory bowel disease. Neoadjuvant radiotherapy/chemoradiotherapy was given to 55% and 63% of patients with and without inflammatory bowel disease respectively. The median follow-up time was 5.2 years (interquartile range (i.q.r.) 2.3-10) in patients with inflammatory bowel disease and 5.9 years (i.q.r. 2.9-10) in patients without inflammatory bowel disease. Based on the adjusted proportional hazards model, no overall difference in recurrence-free survival was found (HR 1.05, 95% c.i. 0.87 to 1.26). In the time-dependent adjusted model, patients with rectal cancer with inflammatory bowel disease experienced a lower recurrence-free survival during the first year after surgery (1 year HR 1.36, 95% c.i. 1.06 to 1.73), after which there was no difference in comparison with patients without inflammatory bowel disease (5 years HR 0.77, 95% c.i. 0.56 to 1.06).</p><p><strong>Conclusion: </strong>Despite lower recurrence-free survival during the first year among those with inflammatory bowel disease, there were no long-term differences between patients with or without inflammatory bowel disease.</p>","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":"9 2","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Global wealth disparities drive adherence to COVID-safe pathways in head and neck cancer surgery.","authors":"","doi":"10.1093/bjsopen/zraf031","DOIUrl":"10.1093/bjsopen/zraf031","url":null,"abstract":"","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":"9 2","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"α-Fetoprotein model versus Milan criteria in predicting outcomes after hepatic resection for hepatocellular carcinoma: multicentre study.","authors":"Chao Li, Yong-Kang Diao, Yi-Fan Li, Shao-Dong Lv, Xian-Ming Wang, Xue-Dong Wang, Qi-Xuan Zheng, Hong Wang, Han Liu, Kong-Ying Lin, Ying-Jian Liang, Ya-Hao Zhou, Wei-Min Gu, Ming-Da Wang, Lan-Qing Yao, Xin-Fei Xu, Jia-Hao Xu, Li-Hui Gu, Timothy M Pawlik, Feng Shen, Tian Yang","doi":"10.1093/bjsopen/zraf041","DOIUrl":"10.1093/bjsopen/zraf041","url":null,"abstract":"<p><strong>Background: </strong>The Milan criteria and the French α-fetoprotein (AFP) model have both been validated for predicting outcomes after liver transplantation for hepatocellular carcinoma, with the Milan criteria also used for predicting outcomes after hepatic resection. The aim of this study was to evaluate the AFP model's predictive value for recurrence and survival following hepatocellular carcinoma resection and compare its performance with that of the Milan criteria.</p><p><strong>Methods: </strong>Data for patients who underwent hepatocellular carcinoma resection between 2002 and 2021 were analysed. For both the AFP model and Milan criteria, patients were divided into two groups: those with hepatocellular carcinoma within and beyond the AFP model (scores ≤ 2 and > 2 points, respectively) and the Milan criteria. Cumulative recurrence and overall survival rates were compared between patients within and beyond the AFP model. Predictions of recurrence and overall survival by the AFP model and Milan criteria were compared using net reclassification improvement and area under the receiver operating characteristic curve analyses.</p><p><strong>Results: </strong>Among 1968 patients evaluated, 1058 (53.8%) and 940 (47.8%) were classified as beyond on the AFP model and Milan criteria, respectively. After controlling for competing factors on multivariable analyses, being beyond the AFP model was independently associated with recurrence and worse overall survival after resection of hepatocellular carcinoma. Time-dependent net reclassification improvement and area under the receiver operating characteristic curve analyses demonstrated that the AFP model was superior to the Milan criteria in predicting recurrence. Of note, patients who were classified as beyond both the Milan criteria and AFP model had an even higher risk of postoperative recurrence and mortality (hazard ratios 1.51 and 1.47, respectively).</p><p><strong>Conclusion: </strong>The French AFP model demonstrated superior prognostic accuracy to the Milan criteria in predicting recurrence and survival after hepatocellular carcinoma resection. The AFP model not only effectively stratified patient risk but also identified a subgroup of high-risk patients among those beyond the Milan criteria.</p>","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":"9 2","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11979696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perineal wound complications after total neoadjuvant therapy or chemoradiotherapy followed by abdominoperineal excision in patients with high-risk locally advanced rectal cancer in the RAPIDO trial.","authors":"Wouter H Zwart, Esmée A Dijkstra, Geke A P Hospers, Corrie A M Marijnen, Hein Putter, Joakim Folkesson, Cornelis J H Van de Velde, Annet G H Roodvoets, Elma Meershoek-Klein Kranenbarg, Bengt Glimelius, Boudewijn Van Etten, Per J Nilsson","doi":"10.1093/bjsopen/zraf043","DOIUrl":"10.1093/bjsopen/zraf043","url":null,"abstract":"<p><strong>Background: </strong>Perineal wound complications (PWCs) occur in 15-30% of patients after abdominoperineal excision (APE) and are associated with adverse events, such as delayed wound healing, prolonged hospitalization, a delay in initiating postoperative chemotherapy, and decreased quality of life. Preoperative radiotherapy and chemotherapy are risk factors for wound complications. It is unknown whether total neoadjuvant treatment (TNT) affects the risk of PWCs compared with chemoradiotherapy (CRT).</p><p><strong>Methods: </strong>This study compared patients from the experimental (EXP; short-course radiotherapy, chemotherapy, and surgery as TNT) and standard-of-care (STD; CRT, surgery, and postoperative chemotherapy depending on hospital policy) treatment arms of the RAPIDO trial who underwent APE within 6 months after preoperative treatment. The primary outcome was the incidence of PWCs (infection, abscess, dehiscence, wound discharge, presacral abscess affecting the perineum) of any grade ≤ 30 days after APE. Secondary outcomes were the incidence of PWCs >30 days after APE, length of hospital stay, characteristics associated with PWCs, and oncological outcomes in patients with versus without PWC.</p><p><strong>Results: </strong>Of the 901 patients who started treatment (460 in EXP arm, 441 in STD arm), 153 (33%) and 160 (36%) underwent APE after TNT and CRT, respectively. After TNT and CRT, the incidence of PWCs ≤30 days after APE, readmission, and reoperation was 54 of 153 (35%) versus 53 of 160 (33%) (P = 0.69), 9% versus 12% (P = 0.54), and 7% versus 8% (P = 0.75), respectively. The median length of hospital stay was 2-3 days longer for patients with PWC. Univariable analysis revealed that pretreatment albumin <35 g/l, hypertension, and haemoglobin ≤ 8.0 mmol/l were associated with PWC. Oncological outcomes were similar between patients with and without PWCs.</p><p><strong>Conclusion: </strong>In the RAPIDO trial, TNT and CRT resulted in a similar incidence of PWCs among patients with high-risk locally advanced rectal cancer who underwent APE.</p>","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":"9 2","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12022605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic versus laparoscopic hepatectomy: meta-analysis of propensity-score matched studies.","authors":"Piao Wang, Dan Zhang, Bin Huang, Wen-Hao Zhou, Chang-Song Wang, Shao-Yong Zhao, Song Su, Xiao-Zhong Jiang","doi":"10.1093/bjsopen/zrae141","DOIUrl":"10.1093/bjsopen/zrae141","url":null,"abstract":"<p><strong>Background: </strong>Robotic techniques can theoretically overcome the limitations of laparoscopic liver resection and are currently recognized as safe options; however, it is not known which approach is better. The purpose of this study was to compare the advantages of robotic hepatectomy and laparoscopic hepatectomy.</p><p><strong>Methods: </strong>Electronic databases (the Cochrane Library, PubMed (MEDLINE), Embase and Web of Science) were systematically searched from January 2000 to August 2023 for eligible studies that compared robotic hepatectomy and laparoscopic hepatectomy. Studies that met the inclusion criteria were then reviewed systematically. The reported data were aggregated statistically using RevMan 5.4 software. The parameters of interest included intraoperative, postoperative, survival and financial outcomes. Subgroup analysis was performed according to the type and difficulty level of hepatectomy and the study setting.</p><p><strong>Results: </strong>A total of 26 propensity-score matching comparative trials met the inclusion criteria, which comprised 9355 participants (robotic hepatectomy versus laparoscopic hepatectomy: 3938 versus 5417) in the meta-analysis. For surgical outcomes, lower blood loss, lower open conversion rate and higher R0 resection rate were observed in the robotic hepatectomy group compared with the laparoscopic hepatectomy group (mean difference (MD) -86.22, 95% c.i. -116.49 to -55.95, I² = 87%, P < 0.001; OR 0.51, 95% c.i. 0.38 to 0.69, I² = 40%, P < 0.001; OR 1.31, 95% c.i. 1.03 to 1.67, I² = 0%, P = 0.030 respectively). The lower blood loss (major hepatectomy group: MD -56.88, 95% c.i. -109.09 to -4.28, I² = 76%, P = 0.030; IWATE score (advanced/expert more than 80%) group: MD -0.61, 95% c.i. -1.14 to -0.08, I² = 95%, P < 0.001) and lower open conversion rate (major hepatectomy group: OR 0.41, 95% c.i. 0.30 to 0.56, I² = 0%, P < 0.001; IWATE score (advanced/expert less than 80%) group: OR 0.52, 95% c.i. 0.36 to 0.75, I² = 0%, P = 0.659) advantage persisted across subgroup analyses.</p><p><strong>Conclusion: </strong>The robotic approach had advantages to laparoscopic in terms of lower blood loss and reduced rates of open conversion, especially in difficult hepatectomies.</p>","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":"9 2","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11957917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of a low-glycaemic-index formula on post-gastrectomy hypoglycaemia in patients with gastric cancer: randomized crossover study.","authors":"Takeshi Kubota, Takuma Ohashi, Keiji Nishibeppu, Kazuya Takabatake, Hiroyuki Inoue, Yudai Nakabayashi, Hirotaka Konishi, Atsushi Shiozaki, Hitoshi Fujiwara, Emi Ushigome, Michiaki Fukui, Eigo Otsuji","doi":"10.1093/bjsopen/zraf001","DOIUrl":"10.1093/bjsopen/zraf001","url":null,"abstract":"<p><strong>Background: </strong>Patients undergoing gastrectomy often experience postprandial hypoglycaemia, late dumping syndrome, and night-time hypoglycaemia. However, countermeasures for post-gastrectomy hypoglycaemia rely on the patients' own efforts. We sought to investigate how post-gastrectomy hypoglycaemia could be nutritionally improved in patients with gastric cancer.</p><p><strong>Method: </strong>Single-centre prospective, open-labelled, randomized crossover study including patients aged 20-80 years diagnosed with gastric adenocarcinoma, which have undergone total or distal gastrectomy 1-5 years before the study. The patients consumed 100 ml of a low-carbohydrate/high-monounsaturated fatty acid formula orally 30 min after meals and before sleep (400 kcal/day) during the first or second half of a 14-day glucose-monitoring period. The effects of the low-carbohydrate/high-monounsaturated fatty acid formula on the time below range, that is, the percentage of time during which the glucose concentration was <70 mg/dl, and the coefficient of variation (CV) of the glucose concentration when the ideal time below range and CV were set at <5% and ≤36% respectively were assessed. Dumping symptoms were investigated before and after the study.</p><p><strong>Results: </strong>Thirty-eight patients were included in this study. In patients who had undergone total gastrectomy, the (median) daytime time below range, daytime CV, and night-time time below range remained high at 7.6% ((range) 0.0-45.0), 35.6% ((range) 9.5-50.5), and 10.8% ((range) 0.0-56.3) respectively, even after a long postoperative period. The (median) night-time time below range in patients who had undergone distal gastrectomy and total gastrectomy improved from 3.5% ((range) 0.0-47.9) to 1.4% ((range) 0.0-26.6) (P < 0.001, effect size 0.58) and 10.8% ((range) 0.0-56.3) to 9.4% ((range) 0.0-39.9) (P = 0.078, effect size 0.45) respectively. However, the daytime time below range and CV, as indicators of late dumping syndrome, did not change.</p><p><strong>Conclusion: </strong>The low-carbohydrate/high-monounsaturated fatty acid formula improved post-gastrectomy night-time hypoglycaemia, but not daytime glycaemic variability or hypoglycaemia. Thus, further investigation of nutritional optimization is required.</p><p><strong>Clinical trial registration: </strong>Japan Registry of Clinical Trials, jRCT https://jrct.niph.go.jp/, identifier jRCTs s051210200.</p>","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":"9 2","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Video-based coaching for surgeons in the UK: consensus on essential elements.","authors":"Eilidh G M Gunn, Adam P Johnson, Riinu Pius, Douglas S Smink, Andrew L Tambyraja, Steven Yule","doi":"10.1093/bjsopen/zraf006","DOIUrl":"10.1093/bjsopen/zraf006","url":null,"abstract":"","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":"9 2","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143655997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laparoscopic versus open repair of perforated peptic ulcer: systematic scoping review and in-depth evaluation of existing evidence.","authors":"Katy A Chalmers, Matthew J Lee, Sian E Cousins, Adam Peckham Cooper, Peter O Coe, Natalie S Blencowe","doi":"10.1093/bjsopen/zrae163","DOIUrl":"10.1093/bjsopen/zrae163","url":null,"abstract":"<p><strong>Background: </strong>Perforated peptic ulcer remains a common contributor to morbidity and mortality rates worldwide. In common with other emergency surgery conditions, there is a trend towards minimally invasive surgery. This review aims to describe current evidence comparing open and laparoscopic management strategies for perforated peptic ulcers, by summarizing patients, intervention, comparator, outcomes, describing intervention components and delivery, outcomes reported and assessing study pragmatism (applicability) using PRagmatic Explanatory Continuum Indicator Summary-2.</p><p><strong>Methods: </strong>Systematic searches of published literature were performed using Ovid MEDLINE and Embase online databases, as well as clinical trial databases. Randomized trials comparing laparoscopic and open repair of peptic ulcer were included. Data extracted included study metadata, patients, intervention, comparator, outcomes elements, technical aspects of interventions and use of co-interventions, and surgeon learning curves/experience. Applicability was assessed using the PRagmatic Explanatory Continuum Indicator Summary-2 tool, to explore whether trials were predominantly pragmatic or explanatory, and study validity assessed using the Cochrane Risk-of-Bias 2 tool.</p><p><strong>Results: </strong>A total of 408 studies were screened for eligibility, with nine finally included (880 patients). Incision, ulcer closure details and lavage were the most frequently reported aspects of laparoscopic repair. Co-interventions such as antibiotic use and analgesia were reported in most articles, whilst nutrition and Helicobacter pylori eradication were not reported. Interventions were generally delivered by high-volume laparoscopic surgeons. Studies were considered at high Risk-of-Bias. PRagmatic Explanatory Continuum Indicator Summary-2 assessment found studies were neither fully pragmatic nor explanatory.</p><p><strong>Conclusion: </strong>Laparoscopic repair of perforated peptic ulcer is a variably defined intervention. Consideration of how intervention components and co-interventions should be optimally delivered is required to facilitate a well designed randomized trial.</p>","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":"9 2","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143565904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short disease-specific quality of life questionnaire for patients with uncomplicated symptomatic cholecystolithiasis: Gall-Questionnaire.","authors":"Floris M Thunnissen, Daan J Comes, Verena N N Kornmann, Lindsey C F de Nes, Frans T W E van Workum, Sarah Z Wennmacker, Jose A E Custers, Philip R de Reuver","doi":"10.1093/bjsopen/zraf025","DOIUrl":"10.1093/bjsopen/zraf025","url":null,"abstract":"","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":"9 2","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11979450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant treatment versus upfront surgery in borderline resectable and resectable pancreatic ductal adenocarcinoma: meta-analysis.","authors":"Luke D Dickerson, Jayden Gittens, Chris Brunning, Richard Jackson, Michael C Schmid, Ainhoa Mielgo, Daniel Palmer, Christopher M Halloran, Paula Ghaneh","doi":"10.1093/bjsopen/zrae172","DOIUrl":"10.1093/bjsopen/zrae172","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer prognosis remains poor despite advances in adjuvant treatment. Neoadjuvant treatment may improve survival and disease-free survival. This meta-analysis evaluates the outcomes for patients with borderline-resectable (borderline-resectable pancreatic cancer) or resectable disease (resectable pancreatic cancer) in randomized trials of neoadjuvant therapy versus upfront surgery.</p><p><strong>Methods: </strong>The review was performed according to PRISMA guidance. Articles were included from the start of the database until 1 May 2024. The primary outcome was overall survival. Secondary outcomes were progression-free survival, resection rate, R0 rate, N0 rate, vascular resection rate, surgical complications, significant adverse events and rates of adjuvant therapy. Data was collected from study manuscripts or through individual patient-level data extraction. Meta-analysis was performed using a random-effects model with subgroup comparisons for resectability status (resectable pancreatic cancer versus borderline-resectable pancreatic cancer) and treatment modality (chemotherapy versus chemoradiotherapy).</p><p><strong>Results: </strong>Nine trials were included representing 1194 patients. Four trials recruited borderline-resectable pancreatic cancer, four resectable pancreatic cancer and one both. Four trials reported chemotherapy, four chemoradiotherapy and one both treatments. Neoadjuvant treatment improved overall survival (HR 0.73, 95% c.i. 0.55 to 0.98; P = 0.001) and progression-free survival (HR 0.80, 95% c.i. 0.65 to 0.99; P = 0.041). Subgroup analysis demonstrated neoadjuvant treatment improved overall survival for borderline-resectable pancreatic cancer (HR 0.60, 95% c.i. 0.38 to 0.96) but not resectable pancreatic cancer (HR 0.90, 95% c.i. 0.63 to 1.28). The overall resection rate was lower in neoadjuvant treatment (72.6% versus 80.6%, RR 0.94, 95% c.i. 0.89 to 0.99; P = 0.020). R0 rate (43.8% versus 23.0%, RR 1.35, 95% c.i. 1.16 to 1.57; P = 0.002) and N0 rate (30.9% versus 15.0%, RR 2.03, 95% c.i. 1.50 to 2.74; P = 0.001) was improved in neoadjuvant treatment. Significant adverse events occurred more frequently in neoadjuvant treatment (56.1% versus 27.0%, RR 1.92, 95% c.i. 1.28 to 1.89; P = 0.007).</p><p><strong>Conclusion: </strong>Neoadjuvant treatment significantly improves survival in borderline-resectable pancreatic cancer but not resectable pancreatic cancer. It should be regarded as standard of care for these patients. Further work is needed to identify the optimum neoadjuvant regimen and a possible role in the treatment of resectable pancreatic cancer.</p>","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":"9 2","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}